BIO gets a new chief lobbyist to face off against the growing ranks of critics in Congress
BIO has selected its next CEO to succeed James Greenwood as one of biotech’s top lobbyists. And she comes with a dream résumé that rings all the right bells — except for one.
She’s never served in Congress as an elected official.
Harvard-educated with an MD from Duke, Michelle McMurry-Heath got the job after spending more than 5 years largely centered on regulatory work for J&J, specializing in devices. That gives her plenty of Big Pharma insight into the FDA that will help in influencing a key government agency. Even better, she jumped to industry from the FDA, where she was associate director for science, center for devices and radiological health.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.